MC 02331

Cephalosporin
Microcide Pharmaceuticals (Essential Therapeutics [Ceased])
1996
  • Gram-positive activity

  • Highest development stage: Preclinical

  • Combination therapy: In combination with gentamicin, MC-02331 worked synergistically to kill gentamicin susceptible enterococci.

  • Development dropped

  • Mechanism of Action/Target pathogen: Mice infected with S. aureus, were treated with ampicillin (100mg/kg), vancomycin (30mg/kg) or MC-02331 (1, 10 and 30mg/kg). MC-02331 was more active than both vancomycin and ampicillin